Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- May 31 2003
- Volume 10
- Issue 10
Government at Work?
Advertisement
We all know the federal government can spend money, but a look at real numbers and their correspondence to the gross domestic product (GDP) makes it seem all the more staggering. If only your pay as a physician could shoot up as handsomely as these figures.
Articles in this issue
about 18 years ago
Psychiatry in Finance Is a Sobering Thoughtabout 18 years ago
Add LTC Insurance to Your Estate Plansabout 18 years ago
Be a Guest at a Classic Hollywood Hotelabout 18 years ago
Get the Scoop on This Summer's US Openabout 18 years ago
Cinema Consults: TWO WEEKS NOTICEabout 18 years ago
In Memorium: Margaret Anderson (February 1, 1931-March 29, 2003)about 18 years ago
Incorporate Rules into Your Market Planabout 18 years ago
Don't Believe in Santa Claus Annuitiesabout 18 years ago
Weigh the Facts in Investing Tendenciesabout 18 years ago
When the Majority Agree, They're WrongAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care
5